Stephenson Callum, Kumar Anchan, Malakouti Niloufar, Nikjoo Niloofar, Jagayat Jasleen, Gizzarelli Tessa, Patel Charmy, Gutierrez Gilmar, Shirazi Amirhossein, Yang Megan, Omrani Mohsen, Alavi Nazanin
Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
JMIR Res Protoc. 2023 Sep 20;12:e48899. doi: 10.2196/48899.
Generalized anxiety disorder (GAD) is a prevalent anxiety disorder, with cognitive behavioral therapy (CBT) being the gold standard treatment. However, it is inaccessible and costly to many, as the mental health industry is overwhelmed by the demand for treatment. This means effective, accessible, and time-saving strategies must be developed to combat these problems. Web-based interventions for mental health disorders are an innovative and promising way to address these barriers. While electronically delivered CBT (e-CBT) has already proved productive and scalable for treating anxiety, other less resource-intensive interventions can be innovated. Checking up on mental health face-to-face has been shown to provide similar benefits to patients with anxiety disorders previously, but more research is needed to evaluate the efficacy of web-based delivery of this intervention.
This study will compare the efficacy of e-CBT and a web-based mental health check-in program to treat GAD. These programs will both be delivered through a secure, web-based care delivery platform.
We will randomly allocate participants (N=100) who are 18 years or older with a confirmed diagnosis of GAD to either an e-CBT program or a mental health check-in program over 12 weeks to address their anxiety symptoms. Participants in the e-CBT arm will complete predesigned modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform. Participants in the mental health check-in arm will be contacted weekly through the web-based platform's written chat feature (messaging system). Therapists will ask the participants a series of predesigned questions that revolve around a different theme each week to prompt conversation. Using clinically validated questionnaires, the efficacy of the e-CBT arm will be compared to the mental health check-in arm. These questionnaires will be completed at baseline, week 6, and week 12.
The study received ethics approval in April 2021, and participant recruitment began in May 2021. Participant recruitment has been conducted through targeted advertisements and physician referrals. Complete data collection and analysis are expected to conclude by August 2023. Linear and binomial regression (continuous and categorical outcomes, respectively) will be conducted.
To the research team's knowledge, this will be the first study to date comparing the efficacy of e-CBT with a web-based mental health check-in program to treat GAD. The findings from this study can help progress the development of more scalable, accessible, and efficacious mental health treatments.
ClinicalTrials.gov NCT04754438; https://classic.clinicaltrials.gov/ct2/show/NCT04754438.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/48899.
广泛性焦虑障碍(GAD)是一种常见的焦虑症,认知行为疗法(CBT)是其金标准治疗方法。然而,由于心理健康行业的治疗需求不堪重负,许多人无法获得这种治疗且成本高昂。这意味着必须制定有效、可及且节省时间的策略来应对这些问题。基于网络的心理健康障碍干预措施是解决这些障碍的一种创新且有前景的方式。虽然电子交付的认知行为疗法(e-CBT)已被证明在治疗焦虑方面富有成效且可扩展,但可以创新其他资源消耗较少的干预措施。此前研究表明,面对面检查心理健康对焦虑症患者有类似益处,但需要更多研究来评估基于网络交付这种干预措施的效果。
本研究将比较e-CBT和基于网络的心理健康检查程序治疗广泛性焦虑障碍的疗效。这些程序都将通过一个安全的基于网络的护理交付平台提供。
我们将把18岁及以上确诊为广泛性焦虑障碍的参与者(N = 100)随机分配到e-CBT程序或心理健康检查程序中,为期12周以解决他们的焦虑症状。e-CBT组的参与者将完成预先设计的模块和家庭作业任务,同时通过该平台获得个性化反馈并与治疗师进行异步互动。心理健康检查组的参与者将通过基于网络平台的书面聊天功能(消息系统)每周接受联系。治疗师将向参与者询问一系列预先设计的问题,这些问题每周围绕一个不同的主题展开以促进对话。使用经过临床验证的问卷,将e-CBT组的疗效与心理健康检查组进行比较。这些问卷将在基线、第6周和第12周完成。
该研究于2021年4月获得伦理批准,参与者招募于2021年5月开始。参与者招募通过定向广告和医生推荐进行。预计完整的数据收集和分析将于2023年8月结束。将进行线性回归和二项式回归(分别用于连续和分类结果)。
据研究团队所知,这将是迄今为止第一项比较e-CBT与基于网络的心理健康检查程序治疗广泛性焦虑障碍疗效的研究。本研究的结果有助于推动开发更具可扩展性、可及性和有效性的心理健康治疗方法。
ClinicalTrials.gov NCT04754438;https://classic.clinicaltrials.gov/ct2/show/NCT04754438。
国际注册报告识别码(IRRID):DERR1-10.2196/48899。